Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07461493 · ClinicalTrials.gov registry record

The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care

A clinical trial of Cancer and Cancer Comorbidities, sponsored by National Minority Quality Forum.

Recruiting
Registry status
100,000
Enrollment target
2
Study locations

NCT07461493: Recruiting study of Cancer and Cancer Comorbidities, sponsored by National Minority Quality Forum.

NCT07461493 is a study of Cancer and Cancer Comorbidities that is actively recruiting participants, run by National Minority Quality Forum. The registered enrollment target is 100,000 participants, above the 3,329-participant average among 615 other Cancer trials with a reported enrollment target (2904% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07461493, a study of Cancer and Cancer Comorbidities, is actively recruiting participants, sponsored by National Minority Quality Forum.

RECRUITING
Registry status
100,000 participants
Enrollment target
2
Study locations

Study Summary

The goal of this observational study is to establish a patient registry and a biorepository (sample collection and storage) to investigate health disparities, access, and barriers to cancer screening and early detection technologies. The registry and biorepository will serve as a resource to support Cancer Early Detection (CED) screenings and future research focused on communities at increased risk for cancer. The study seeks to address: •Barriers and disparities in cancer prevention, screening, and treatment, particularly in historically underrepresented populations. Participants will: * Attend a minimum of five clinic visits over a five-year period for scheduled annual assessments while actively enrolled in the study. * Complete questionnaires at each visit that collect information on their medical history, cancer history, and family cancer history. * Allow relevant health information from their electronic health records (EHR) to be collected and reviewed. * Provide blood, saliva, and stool samples for research purposes. * Enter a long-term follow-up period for an additional five years.

Primary Outcome

The primary objective of this study is to establish a patient registry that collects and characterizes health data from marginalized and underserved communities.

Study Locations (2)

Michigan

  • Life in 3D Health Services - Flint

Texas

  • Grace Clinic - Houston

Trial Details

FieldValue
Enrollment Target 100,000 participants
Start Date 2025-03-11
Est. Completion 2039-03
National Minority Quality Forum

1 total trials

What NCT07461493 shows while recruiting

NCT07461493 is an observational study that tracks outcomes without assigning an intervention. Its 100,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,329-participant average among 615 other Cancer trials with a reported enrollment target (2904% higher).

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT07461493 reports a single indexed study location in Michigan, Texas.

Frequently Asked Questions

What is clinical trial NCT07461493 about?

NCT07461493 is a clinical study titled "The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care". The goal of this observational study is to establish a patient registry and a biorepository (sample collection and storage) to investigate health disparities, access, and barriers to cancer screening and early detection technologies. The registry and biorepository will serve as a resource to support...

What is the current status of trial NCT07461493?

This trial is currently recruiting. The enrollment target is 100,000 participants. The study started on 2025-03-11. Estimated completion is 2039-03.

What conditions does trial NCT07461493 study?

This clinical trial studies the following conditions: Cancer, Cancer Comorbidities.

Who is sponsoring clinical trial NCT07461493?

This trial is sponsored by National Minority Quality Forum, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07461493 being conducted?

This trial has 2 study locations across Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07461493's enrollment target sits among peer trials

100,000 5th of 615 higher than 609 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02620852 · 100,000 participants · NA

    Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

  • NCT03277365 · 100,000 participants · NA

    MyGeneRank: A Digital Platform for Next-Generation Genetic Studies

  • NCT04281823 · 100,000 participants

    DeBakey Cardiovascular Magnetic Resonance Study

  • NCT04869111 · 100,000 participants · NA

    The BrainHealth Project

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07461493, the US trial registry maintained by the National Library of Medicine. NCT07461493 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.